ストックスクリーナーアプリを入手
0.90
1.69%
0.015
前日終値:
$0.885
開ける：
$0.858
24時間の取引高:
67,540
Relative Volume:
0.36
時価総額：
$168.71M
収益：
$3.91M
当期純損益:
$-206.53M
株価収益率:
-0.3625
EPS:
-2.4825
ネットキャッシュフロー:
$-167.78M
1週間 パフォーマンス:
+2.27%
1か月 パフォーマンス:
+6.97%
6か月 パフォーマンス:
-13.46%
1年 パフォーマンス:
-49.15%
1日の値動き範囲:
$0.858
$0.93
1週間の範囲:
$0.8525
$0.95
52週間の値動き範囲:
$0.595
$2.00
I Mab Adr Stock (IMAB) Company Profile
IMAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMAB
I Mab Adr
|
0.90 | 71.72M | 3.91M | -206.53M | -167.78M | -2.4825 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
I Mab Adr Stock (IMAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-09 | 開始されました | Siebert Williams Shank | Buy |
| 2021-06-02 | 開始されました | Daiwa Securities | Buy |
| 2021-03-15 | 開始されました | Needham | Buy |
| 2021-03-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-25 | 開始されました | Piper Sandler | Overweight |
| 2020-12-07 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-02-12 | 開始されました | China Renaissance | Buy |
| 2020-02-11 | 開始されました | Jefferies | Buy |
すべてを表示
I Mab Adr (IMAB) 最新ニュース
I-Mab’s Financial Report Highlights Givastomig Progress - TipRanks
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 - Barchart.com
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC - Barchart.com
After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance
After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance
I-Mab at Needham Conference: Strategic Transformation Unveiled - Investing.com
I-Mab at Needham Conference: Strategic Transformation Unveiled By Investing.com - Investing.com South Africa
I-Mab’s Transformative Year: Financial and Strategic Highlights - TipRanks
I-Mab stock price target lowered to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa
I-Mab stock price target lowered to $7 at H.C. Wainwright - Investing.com India
I-Mab Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
I-Mab stock touches 52-week low at $0.72 amid market challenges - Investing.com
I-Mab faces Nasdaq delisting over bid price rule By Investing.com - Investing.com South Africa
I-Mab faces Nasdaq delisting over bid price rule - Investing.com
I-Mab advances gastric cancer treatment with swift trial enrollment - Investing.com
I-Mab stock touches 52-week low at $0.76 amid market challenges - Investing.com India
I-Mab ADR (IMAB) stock analysis: A simple moving average approach - US Post News
Use of failure mode and effect analysis to improve the monoclonal antibody drugs management process in pharmacy intravenous admixture services | Scientific Reports - Nature
I-Mab Chairman plans $2 million ADS purchase - Investing.com India
I-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies - MSN
I-Mab names Sean Fu as new CEO - Investing.com
Invitation: Vallourec Q3 2024 Results ReleaseConference Call on Friday, November 15, 2024 - The Manila Times
Analyst Forecast For Grab Holdings Limited (NASDAQ: GRAB) - Stocks Register
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
I-Mab announces clinical trial collaboration with Bristol Myers - TipRanks
Piper Sandler cuts I-Mab stock target to $10, keeps overweight rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis - Nature
I-Mab: Dropping Coverage - Morningstar
I-Mab Full-Year Update Uneventful; Potential Catalysts in H2 2023 - Morningstar
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 - PR Newswire
Morningstar’s Best- and Worst-Performing Stocks: 2022 - Morningstar
Results for A amyloid PET SUVr and B Centiloid scale assessments from study 201 core - ResearchGate
The Cheapest Stock in the World - Morningstar.ca
10 of the Cheapest Stocks of 2022 - Morningstar
Why Are Some China Healthcare Stocks Up 50%? - HK.Morningstar.com
Fig. 3 A Scatchard analysis of 125 I-trastuzumab binding to human... - ResearchGate
Anti-ANGPTL3-FLD monoclonal antibody treatment ameliorates podocyte lesions through attenuating mitochondrial damage - Nature
The Best- and Worst-Performing Stocks: Q3 2022 - Morningstar
Markets Brief: Stocks Fall for the First Time in a Month, More Retail Earnings Ahead - Morningstar
Sabah does not deserve this, MAB! - Daily Express Malaysia
Fig. 2 Flowchart of Sicilian adverse drug reaction (ADR) report... - ResearchGate
Markets Brief: How High Can Mortgage Rates Go? - Morningstar
New 5-Star Stocks - Morningstar
HFCAA News: 128 Chinese Stocks the SEC Could Delist - InvestorPlace
Safety Profile of Monoclonal Antibody Compared With Traditional Anticancer Drugs: An Analysis of Henan Province Spontaneous Reporting System Database - Frontiers
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study - Yahoo Finance
I-MabADR to Host Earnings Call - AccessWire
Citi Appointed as Depositary Bank for I-Mab’s Sponsored ADR Program - Business Wire
Biotech & Pharma News, Stocks, FDA Decision, Clinical Trials - RTTNews
Figure 1: Conventional antibody expression in E. coli. Most of the... - ResearchGate
I Mab Adr (IMAB) 財務データ
収益
当期純利益
現金流量
EPS
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):